The Claim
In mice, the monoclonal antibody SRK-015 selectively inhibits myostatin activation without cross-reacting with GDF11, Activin A, BMP9, BMP10, or TGFβ1, demonstrating that targeting precursor forms enables greater specificity than antibodies targeting mature myostatin.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice, the antibody SRK-015 blocks myostatin activation without affecting related proteins GDF11, Activin A, BMP9, BMP10, or TGFβ1, showing that targeting the precursor form of myostatin achieves higher specificity than targeting the mature form.
See the scientific wording
In mice, the monoclonal antibody SRK-015 selectively inhibits myostatin activation without cross-reacting with GDF11, Activin A, BMP9, BMP10, or TGFβ1, demonstrating that targeting precursor forms enables greater specificity than antibodies targeting mature myostatin.
A specific antibody binds to the inactive form of myostatin before it gets activated, preventing a molecular cutter from splitting it into its active version. Without the active form, muscles stop breaking down and start growing larger and stronger.
What the research says
1 studyStudy: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting
This study shows that SRK-015 is like a smart key that only fits the lock of myostatin before it becomes active, leaving other similar proteins alone—making it more precise than older keys that opened multiple locks by mistake.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.